+ 
  + 
* [Therapeutic
  Areas
* [Our Products
  & Pipeline
* [Press
  Releases
!
# Improving patient quality of life
With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases.
# Our growing portfolio of products
### PANCREAZE® for Exocrine Pancreatic Insufficiency (EPI)
Exocrine pancreatic insufficiency (EPI) is a condition that results from a deficiency in the production and/or secretion of pancreatic enzymes and can lead to chronic diarrhea, significant weight loss and malnutrition. While there is no cure for EPI, PANCREAZE, a pancreatic enzyme replacement therapy, is an effective therapy for managing this chronic disease.
# Latest Press Releases
 January 13, 2025 VIVUS Shares Pipeline at Annual J.P. Morgan Conference      October 30, 2024 VIVUS & UpScriptHealth Announce Launch of ChooseQ.online for Access to Advanced Weight Management Solutions Collaborative Telehealth Platform      October 28, 2024 VIVUS Shares Significant Regulatory Update on QSYMIA   
# VIVUS Locations and Contact Information
To access our corporate contact directories please select from:
**VIVUS LLC**
United States
**VIVUS BV**
Netherlands
**VIVUS AG**
Switzerland
**VIVUS Pharmaceuticals Ltd.**
Canada
# Helpful Links and Resources
**LOCATIONS**
**ABOUT VIVUS**
**FOLLOW US**
Cookies Notice
©2024 VIVUS LLC. All rights reserved. VIVUS0001.09-USP
### You are about to leave the VIVUS LLC website
Links to third-party websites on VIVUS.com are provided solely for your convenience.
VIVUS LLC does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.
Cancel
Continue
# About Us
[Executive
Team
# We are a focused organization
We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.
# Our history
### EXPLORE OUR INTERACTIVE TIMELINE
Learn about the evolution of VIVUS and the expansion of our business globally. Swipe, click through or select a year to navigate our interactive timeline.
SELECT A YEAR:
1991
1994
1997
2003
2005
2007
2009
2010
2012
2013
2014
2016
2018
2019
2020
2022
2023
PREVIOUS
NEXT
1991. VIVUS is founded.
1994. VIVUS completes initial public offering.
1997. U.S. FDA approves MUSE® (alprostadil) reproductive health treatment in the U.S.
2005. VIVUS announces focus on developing obesity treatments.
2009. Two Phase 3 U.S. clinical trial results for QSYMIA® (phentermine and topiramate extended-release capsules) CIV announced.
2010. VIVUS announces sale of MUSE® (alprostadil) reproductive health treatment to Meda.
2012 U.S. FDA approves use of STENDRA® (avanafil)
2012 U.S. FDA approval and launch of QSYMIA® (phentermine and topiramate extended-release capsules) CIV treatment for adult patients in the U.S.
2013 EU EMA approval of SPEDRA® (avanafil)
2014 U.S. FDA approves a supplemental new drug application for the a rapid onset of action for STENDRA® (avanafil)
2016 VIVUS announces license agreement providing commercial rights to STENDRA® (avanafil) to Metuchen Pharmaceuticals
2018 VIVUS acquires all product rights for PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada
2019 South Korean MFDS approves QSYMIA® (phentermine and topiramate extended-release capsules) CIV for adult patients in South Korea
2020 VIVUS receives court approval for process to emerge from proceedings as a wholly-owned subsidiary of Icahn Enterprises L.P.
2020 Launch of QSYMIA® (phentermine and topiramate extended-release capsules) CIV for adult patients in South Korea
2020 U.S. FDA approves QSYMIA® (phentermine and topiramate extended-release capsules) CIV for pediatric patients aged 12-17 in the United States
2022 Market authorizations for QSIVA® (phentermine and topiramate modified-release) hard capsules granted in Sweden, Denmark, Finland, Iceland, Norway, and Poland
2022 VIVUS opens its European headquarters
2023 Initial launch of QSIVA® (phentermine and topiramate modified-release) hard capsules in Europe along with submission of additional individual authorization applications